121 related articles for article (PubMed ID: 26401696)
1. Long-Term Efficacy of Galantamine in Alzheimer's Disease: The Okayama Galantamine Study (OGS).
Nakano Y; Matsuzono K; Yamashita T; Ohta Y; Hishikawa N; Sato K; Deguchi K; Abe K
J Alzheimers Dis; 2015; 47(3):609-17. PubMed ID: 26401696
[TBL] [Abstract][Full Text] [Related]
2. Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS).
Matsuzono K; Yamashita T; Ohta Y; Hishikawa N; Sato K; Kono S; Deguchi K; Nakano Y; Abe K
J Alzheimers Dis; 2015; 46(3):687-93. PubMed ID: 26402513
[TBL] [Abstract][Full Text] [Related]
3. Clinical Benefits of Memantine Treatment for Alzheimer's Disease in the Okayama Memantine Study II (OMS II).
Matsuzono K; Yamashita T; Ohta Y; Hishikawa N; Koike M; Sato K; Kono S; Deguchi K; Nakano Y; Abe K
J Alzheimers Dis; 2015; 47(2):487-93. PubMed ID: 26401570
[TBL] [Abstract][Full Text] [Related]
4. Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study.
Matsuzono K; Hishikawa N; Ohta Y; Yamashita T; Deguchi K; Nakano Y; Abe K
J Alzheimers Dis; 2015; 45(3):771-80. PubMed ID: 25624417
[TBL] [Abstract][Full Text] [Related]
5. Clinical Benefits of Rivastigmine in the Real World Dementia Clinics of the Okayama Rivastigmine Study (ORS).
Matsuzono K; Sato K; Kono S; Hishikawa N; Ohta Y; Yamashita T; Deguchi K; Nakano Y; Abe K
J Alzheimers Dis; 2015; 48(3):757-63. PubMed ID: 26402119
[TBL] [Abstract][Full Text] [Related]
6. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease.
Galasko D; Kershaw PR; Schneider L; Zhu Y; Tariot PN
J Am Geriatr Soc; 2004 Jul; 52(7):1070-6. PubMed ID: 15209643
[TBL] [Abstract][Full Text] [Related]
7. Different clinical effect of four antidementia drugs for Alzheimer's disease patients depending on white matter severity.
Fukui Y; Hishikawa N; Ichinose J; Sato K; Nakano Y; Morihara R; Ohta Y; Yamashita T; Abe K
Geriatr Gerontol Int; 2017 Nov; 17(11):1991-1999. PubMed ID: 28276131
[TBL] [Abstract][Full Text] [Related]
8. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction.
Hishikawa N; Fukui Y; Sato K; Ohta Y; Yamashita T; Abe K
Geriatr Gerontol Int; 2017 Oct; 17(10):1384-1391. PubMed ID: 27578455
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.
Burns A; Bernabei R; Bullock R; Cruz Jentoft AJ; Frölich L; Hock C; Raivio M; Triau E; Vandewoude M; Wimo A; Came E; Van Baelen B; Hammond GL; van Oene JC; Schwalen S
Lancet Neurol; 2009 Jan; 8(1):39-47. PubMed ID: 19042161
[TBL] [Abstract][Full Text] [Related]
11. Cognitive and affective benefits of combination therapy with galantamine plus cognitive rehabilitation for Alzheimer's disease.
Tokuchi R; Hishikawa N; Matsuzono K; Takao Y; Wakutani Y; Sato K; Kono S; Ohta Y; Deguchi K; Yamashita T; Abe K
Geriatr Gerontol Int; 2016 Apr; 16(4):440-5. PubMed ID: 25952367
[TBL] [Abstract][Full Text] [Related]
12. Galantamine treatment in outpatients with mild Alzheimer's disease.
Richarz U; Gaudig M; Rettig K; Schauble B
Acta Neurol Scand; 2014 Jun; 129(6):382-92. PubMed ID: 24461047
[TBL] [Abstract][Full Text] [Related]
13. A naturalistic study of galantamine for Alzheimer's disease.
Brodaty H; Woodward M; Boundy K; Barnes N; Allen G;
CNS Drugs; 2006; 20(11):935-43. PubMed ID: 17044730
[TBL] [Abstract][Full Text] [Related]
14. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
[TBL] [Abstract][Full Text] [Related]
15. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
[TBL] [Abstract][Full Text] [Related]
16. Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease.
Monsch AU; Giannakopoulos P;
Curr Med Res Opin; 2004 Jun; 20(6):931-8. PubMed ID: 15200752
[TBL] [Abstract][Full Text] [Related]
17. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.
Raskind MA; Peskind ER; Truyen L; Kershaw P; Damaraju CV
Arch Neurol; 2004 Feb; 61(2):252-6. PubMed ID: 14967774
[TBL] [Abstract][Full Text] [Related]
18. Acetylcholinesterase inhibition and insulin resistance in late onset Alzheimer's disease.
Isik AT; Bozoglu E
Int Psychogeriatr; 2009 Dec; 21(6):1127-33. PubMed ID: 19631004
[TBL] [Abstract][Full Text] [Related]
19. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Rockwood K; Dai D; Mitnitski A
Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
[TBL] [Abstract][Full Text] [Related]
20. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
